Calissa Therapeutics
Monday, February 26, 2024
Plymouth
Dermatology
Calissa Therapeutics is a clinical stage dermatology company targeting vascular lesions. Our lead indications are rosacea and port wine birthmark, one of the most common birthmarks. Lead asset CX-001 has been approved ex-US with over 30,000 patients treated. The target product profile includes higher/deeper responses, much less frequent treatment and minimal relapse vs. SOC, based on distinctive MOA that might permanently shut down blood vessels. IND was approved by FDA in 2022 and phase 2 study is ongoing.
Speakers
State
NY
Country
United States
Website
http://None, in stealth mode now
CEO/Top Company Official
Jack Hu, Ph.D
Lead Product in Development
CX-001, an innovative therapeutic that was approved ex-US, with 30,000+ patients treated and a run rate of $25m in 2023E; the product gained FDA IND in 2022 and is currently in Phase 2 study in US for capillary malformation
Development Phase of Primary Product
Phase II
Number Of Unlicensed Products
1
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}